BETHESDA, Md.--(BUSINESS WIRE)--Aug. 9, 2006--RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN - News) today announced that it received a $545,000 grant from the U.S. Food and Drug Administration’s (FDA’s) Office of Orphan Products Development (OOPD) for the development of its drug candidate based on Thymosin beta 4 (TB4). The two-year grant will be utilized for RegeneRx’s Phase II Epidermolysis Bullosa (EB) clinical trial, which is currently enrolling patients.
